Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did you get out of MEMY?
Good question.Direct it at Surf and he will answer.
I just checked in today and I'm kind of horrified. Anyone know what happened? I thought a Roche deal was imminent.
Looking for a bounce.Not in yet though.Will go lower looks like.They do have alot of problems right now.
i was looking for .35
risky play though, they got major problems going on from what I hear
Bought back into MEMY this morning, trading position only, looking for a reversal for hopefully up to 50%.
Memory Pharmaceutical Q4 2007 Earnings Call Transcript:
http://seekingalpha.com/article/69286-memory-pharmaceutical-q4-2007-earnings-call-transcript?source=yahoo
They just cut a large number of staff over there last week...
the word I got was that things are very, very F'd up in there
Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
Thursday March 6, 6:05 am ET
- Completes SAD Portion of the Phase 1 Program for R4996/MEM 63908 -
MONTVALE, N.J., March 6 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News), a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system (CNS) conditions, today reported its financial results for the fourth quarter and year ended December 31, 2007.
"We have made significant progress with our clinical and business development efforts in recent months, highlighted by our positive Phase 2a data for MEM 3454 in Alzheimer's disease, the expansion of our schizophrenia development program for MEM 3454 with our partner Roche, and the completion of our single ascending dose Phase 1 study for R4996/MEM 63908," said Vaughn M. Kailian, President & Chief Executive Officer. "During 2008, we look forward to building on this progress as we advance our clinical programs. We expect to complete our ongoing Phase 2a trial for MEM 3454 in cognitive impairment associated with schizophrenia and report top-line data from the study, complete the remaining studies in our Phase 1 program for R4996/MEM 63908, and initiate a biomarker study for MEM 3454 in schizophrenia."
Financial Results
For the quarter ended December 31, 2007, the Company reported a net loss of $9.6 million, or $0.13 per share, compared to a net loss of $14.7 million, or $0.23 per share, for the same period in 2006. For the year ended December 31, 2007, the Company reported a net loss of $35.3 million, or $0.49 per share, compared to a net loss of $31.1 million, or $0.70 per share, in 2006.
For the quarter ended December 31, 2007, the Company reported revenue of $1.1 million, compared to revenue of $2.6 million for the same period in 2006. For the year ended December 31, 2007, the Company reported revenue of $11.5 million, compared to revenue of $9.3 million in 2006. The increase in revenue for the year ended December 31, 2007 is related to recognizing the $2.2 million in milestone payments received from the Stanley Medical Research Institute in connection with the MEM 1003 Phase 2a bipolar disorder clinical trial.
Research and development expenses for the quarter ended December 31, 2007 were $8.3 million compared to $10.5 million for the same period in 2006. The change included a decrease of $3.0 million associated with the clinical development of MEM 1003, offset by an increase of $0.5 million in manufacturing costs. Research and development expenses for the year ended December 31, 2007 were $38.4 million compared to $33.8 million for the same period in 2006. The change included an increase of $4.2 million associated primarily with the clinical development of MEM 3454 and an increase of $0.7 million in personnel and personnel-related costs.
General and administrative expenses for the quarter ended December 31, 2007 were $2.2 million, compared to $1.8 million for the same period in 2006. The change included an increase of $0.4 million in personnel and personnel- related costs. General and administrative expenses for the year ended December 31, 2007 were $9.3 million compared to $8.4 million for the same period in 2006. The change included an increase of $0.8 million in personnel and personnel-related costs.
At December 31, 2007, the Company had cash, cash equivalents and marketable securities of approximately $38.2 million, compared to $51.3 million at the end of 2006. The Company now expects that its existing cash, cash equivalents, and marketable securities, together with payments expected to be made under its collaboration agreements, should be sufficient to fund operating expenses, debt obligations and capital equipment requirements into the first half of 2009.
Fourth Quarter Highlights and Recent Developments
-- Nicotinic Alpha-7 Receptor Agonist Program
MEM 3454. In November 2007, Memory Pharmaceuticals reported positive
top-line results from its Phase 2a trial of MEM 3454, a nicotinic
alpha-7 receptor agonist, in Alzheimer's disease, demonstrating a
statistically significant effect on multiple measures of cognition.
In December 2007, the Company commenced a Phase 2a trial of MEM 3454
in cognitive impairment associated with schizophrenia (CIAS). The
trial is expected to enroll approximately 160 patients and is designed
to assess the safety, tolerability and cognitive effects of three
doses of MEM 3454 in patients with CIAS. The Company plans to
announce top-line results from this trial in the fourth quarter of
2008.
In February 2008, Memory Pharmaceuticals announced that it plans to
conduct a clinical study of MEM 3454 on two biomarkers of
schizophrenia, P50 sensory gating and mismatch negativity, in patients
with schizophrenia. The biomarker study, and additional formulation
and manufacturing activities for MEM 3454, will be funded by Roche.
The Company expects to begin the study this summer, with data
available by early 2009.
R4996/MEM 63908. Memory Pharmaceuticals reported today that it has
completed the single ascending dose (SAD) portion of its Phase 1 study
for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7
receptor. The randomized, double-blind, placebo-controlled study
evaluated the safety, tolerability and pharmacokinetics of ascending
doses of R4996/MEM 63908 in healthy adult male volunteers. As part of
the Phase 1 clinical program for R4996/MEM 63908, the Company is now
conducting a food interaction study in healthy adult male volunteers
and a randomized, placebo-controlled single dose study in elderly male
and female volunteers, and plans to commence a multiple ascending dose
study. The Company now expects to announce the top-line data from the
Phase 1 program in the fourth quarter of 2008.
-- MEM 1003. In October 2007, Memory Pharmaceuticals announced top-line
data from its Phase 2a study of MEM 1003 in Alzheimer's disease. The
trial failed to meet its primary endpoint, which was a twelve-week
mean change in the Alzheimer's disease Assessment Scale -- Cognitive
subscale (ADAS-cog) score in the overall population, due primarily to
an unusually large placebo response in the subgroup of monotherapy
subjects. In the subgroup of subjects receiving cholinesterase
inhibitors, the change in ADAS-cog favored treatment over placebo and
numeric improvements were seen in all of the four secondary endpoints.
The Company plans to complete its analysis of the data from this trial
and evaluate the potential for further development of this drug
candidate.
-- Leadership Team
Interim President and Chief Executive Officer. In February 2008,
Memory Pharmaceuticals appointed Vaughn M. Kailian interim President
and Chief Executive Officer. Jim Sulat, the Company's President and
Chief Executive Officer since 2005, stepped down for personal family
reasons and will serve as the Company's Chief Financial Officer on a
part-time basis. In support of Mr. Kailian's appointment, four of the
Company's largest shareholders, MPM Capital, Great Point Partners,
Oxford Biosciences and Venrock, agreed to a six-month lock-up
agreement. The Board has commenced a search for a full-time Chief
Executive Officer.
New Board Member. In November 2007, Paul Blake, M.B., currently
Senior Vice President and Chief Medical Officer of AEterna Zentaris
Inc., joined Memory Pharmaceuticals' Board of Directors. Dr. Blake
has over 27 years of clinical development experience, including
previous positions at Avigenics Inc., Cephalon, Inc., MDS Proteomics,
Inc. and SmithKline Beecham Pharmaceuticals.
Conference Call and Webcast Information
Memory Pharmaceuticals will hold a conference call on March 6, 2008, at 9:00 a.m. EST to discuss the Company's fourth quarter and full year 2007 financial results. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:
Date: Thursday, March 6, 2008
Time: 9:00 a.m. EST
Telephone (U.S.): 800.599.9829
Telephone (international): 617.847.8703
Participant Passcode: 91069592
Webcast: http://www.memorypharma.com
under the "Investors" section
An audio replay of the conference call will be available from 11:00 a.m. EST on Thursday, March 6, 2008, until Thursday, March 13, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 63677090. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.
I think before the major run thye will run it up and down a few times.
Started buying back some MEMY yesterday, sold half on the spike and I was surprised it dropped back so quickly. I thought I would be selling the other half at $1.
Surf posted it in post 70.
http://www.form4oracle.com/company?cik=0001062216&ticker=memy
Take Care.
any link for 1 million insider buy?
so quiet today ?_?
We should see a mini run today.
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Tuesday February 19, 6:05 am ET
- Establishes Plan for Biomarker Study -
MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia. The biomarker study, and additional formulation and manufacturing activities for MEM 3454, will be funded by Roche, under the companies' collaboration for the development of nicotinic alpha-7 receptor agonists.
"This new study will greatly enhance our ability to measure and predict the efficacy of MEM 3454 and other compounds in the nicotinic alpha-7 receptor program," said Stephen Murray, MD, Ph.D, Chief Medical Officer of Memory Pharmaceuticals Corp. "The study should be underway this summer with data available by early 2009. The biomarker data, together with the results of our ongoing Phase 2a study in CIAS, will help with the design of later-stage trials in schizophrenia."
The biomarker study will enroll approximately 12 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects will be randomized to receive MEM 3454 and placebo in a 5-way cross-over design. Each subject will participate in 5 treatment periods. During each period, subjects will receive single doses of 1 mg, 5 mg, 15 mg, or 50 mg of MEM 3454 or placebo, with a 4-day wash-out period between each treatment period. The primary objective of the trial is to study P50 sensory gating and mismatch negativity as potential efficacy biomarkers for nicotinic alpha-7 agonists, such as MEM 3454, in schizophrenia. P50 sensory gating and mismatch negativity are two neurophysiological measurements that have been shown to be closely associated with nicotinic alpha-7 function and schizophrenia.
In November 2007, Memory Pharmaceuticals announced positive Phase 2a data from a clinical trial of MEM 3454 in Alzheimer's disease. MEM 3454 demonstrated a statistically significant effect on cognition at the 5 mg and 15 mg doses on both the primary and key secondary endpoints for that trial. Roche has an option to a worldwide, exclusive license to develop and commercialize MEM 3454 upon the delivery by Memory of the study report of the Phase 2a AD study and the fulfillment of certain additional predefined events. Roche is obligated to make a milestone payment to Memory Pharmaceuticals at the time this option is exercised.
In December 2007, as part of the development program for MEM 3454 in schizophrenia, Memory Pharmaceuticals commenced a Phase 2a clinical trial of MEM 3454 in CIAS. To maintain its license to MEM 3454, Roche would have to make an additional milestone payment to the Company upon completion of the ongoing Phase 2a CIAS trial, which is expected to be completed in the fourth quarter of 2008.
http://biz.yahoo.com/prnews/080219/nytu035.html?.v=101
Thanks.GL.
great call!
and you catched on right time.
i got some at 65cents.
and chart is so sweet!
You did, eh. I failed to get the alert, but at least it showed up in my scan on Friday!
I alerted MEMY at 50c. We will be @ $1.50 in two weeks time. JMHO
No, but it will get there imo, just give it some time.
This should put some juice in the stock:
Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
Thursday February 7, 4:15 pm ET
MONTVALE, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that Vaughn M. Kailian has been appointed interim President & Chief Executive Officer. In support of Mr. Kailian's appointment, four of the Company's largest shareholders, MPM Capital, Great Point Partners, Oxford Biosciences and Venrock, have agreed to a six-month lock-up agreement. Jim Sulat, who has served as the Company's President & Chief Executive Officer since 2005, has decided to step down from this position for personal family reasons and will serve as the Company's Chief Financial Officer on a part-time basis.
"Memory Pharmaceuticals is a company with an excellent pipeline of clinical and preclinical programs, a strong scientific foundation, a wealth of talent and great potential. I am excited about the opportunity to capitalize on these strengths as we work to maximize our assets and generate significant additional shareholder value," stated Vaughn Kailian. "I will work closely with the management team to review our programs and organizational structure to ensure that they are closely aligned with our goals and that we are well- positioned to achieve our vision for this Company. We expect this review to be completed shortly."
"Through his role as an investor in and a director at Memory Pharmaceuticals for the past two years, Vaughn is uniquely positioned to step in as interim Chief Executive Officer. Vaughn has earned a reputation as one of the most respected leaders in the biotech industry. The combination of his extensive executive experience and his track record in both the pharmaceutical and biotechnology industries makes him the obvious choice to lead Memory Pharmaceuticals during this transition. Vaughn and the Board will now commence the recruiting process for a permanent Chief Executive Officer to lead the Company into the next phase of its development," stated Jonathan Fleming, Chairman of the Board of Directors. "We support Jim in his decision to step down as President & Chief Executive Officer, but are pleased that he will continue to play a leadership role at Memory Pharmaceuticals. Under his stewardship, Memory Pharmaceuticals has evolved into a clinical development organization with a robust pipeline supported by a strong research engine, and we look forward to his continuing contributions to our success."
Mr. Kailian has served as a Managing Director of MPM BioVentures IV LLC since 2005. From February 2002 to December 2004, he served as Vice Chairperson of Millennium Pharmaceuticals, Inc. and as head of the Millennium commercial organization. From 1990 to 2002, Mr. Kailian was the Chief Executive Officer, President, and a director of COR Therapeutics, Inc. He became the CEO of COR shortly after the company was founded, took the company public in 1991, raised almost $1 billion in public market capital, and led its $2 billion merger with Millennium in 2002. Earlier in his career, Mr. Kailian held various international and U.S. general management, marketing and sales positions at Marion Merrell Dow, Inc. and its predecessor companies including president and general manager, Merrell Dow USA; and corporate vice president of Global Commercial Development, Marion Merrell Dow, Inc. In addition to serving as a member of the Company's Board of Directors, Mr. Kailian serves as a director of Cephalon, Inc. and NicOx, S.A., and several privately-held companies. Mr. Kailian also serves as a director of BIO Ventures for Global Health and the New England Healthcare Institute, both not-for-profit organizations. Mr. Kailian received a B.A. from Tufts University.
I'm with you on MEMY not flipping for a couple of pennies, waiting for some real news and buying more when MEMY falls back on these low volume pullbacks.
surf
MEMY(.69) Alerted at .58 :)
Thanks to a friend who alerted me on the stock!!
http://investorshub.advfn.com/boards/read_msg.asp?Message_id=26140282&txt2find=memy
Seems like 3'rd or 4th quarter last year, you could almost bank on a bump from a conference, or at least it seemed that way. Then came the pullback and nothing would move them. Now it will be interesting to see how they are treated.
Take Care.
They do seem to have "mini rallies" into these meetings, and you don't have them if you have really "bad" news to present.
Thanks Surf, I like they are going to present on the 12th. Last Monday/week ago, I bought 100 options on ZMH, who were due to present on Wed. Then next day they pre-announce they were going to beat earnings, and the stock ran 10, options up 4-500%. So I am all over watching companies due to speak!
Take Care.
Also loaded up on MEMY in the past few weeks, check the trading history on this one. It has wild swings and should have more as it tries to make itself a player again.
surf
Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Tuesday February 5, 4:05 pm ET
MONTVALE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that James Sulat, President and Chief Executive Officer, will provide a company update at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 10:15 a.m. ET at The Waldorf=Astoria Hotel in New York City.
http://biz.yahoo.com/prnews/080205/nytu117.html?.v=101
Once investors remember what this stock is all about, they will be back. In fact, a few have dribbled in today. I expect the co to rev this up in the coming weeks, its that delisting thing, get ready.
Drug Markets in Cognitive Dysfunction Will Experience Dramatic Transformation as Total Sales Increase From $300 Million in 2006 to $3.7 Billion in 2016
Launches of New Therapies Will Boost Diagnosis and Drug-Treatment Rates, According to a New Report from Decision Resources
http://www.marketwatch.com/news/story/drug-markets-cognitive-dysfunction-experience/story.aspx?guid=%7B50E3A8B7-1672-463C-B3EA-A2BD5BDC8948%7D&dist=TQP_Mod_pressN
hearing good thing for this one... ;) big move coming soon? tia
Thanks for the excellent article- Good work MEMY
Jogging your memory
Monday, January 7, 2008
You can push your aging brain to recall more facts and dates, scientists say, if you use a little muscle. By Anne Underwood.
Brad Williams, a 51-year-old radio anchor in La Crosse, Wis., used to joke that, if he ever married, he would never forget his anniversary. You wouldn't either, with a memory like his.
RELATED LINKS
Mental as anything
Have your say
Ask him what day of the week Christmas fell on in 1982, and he summons the correct answer in less than two seconds - Saturday. A video that his brother posted on YouTube shows Williams rattling off the answers to such random questions as what day Egyptian President Anwar Sadat was assassinated and what tragic event happened on Nov. 18, 1978. (Oct. 6, 1981, and the Jonestown massacre, respectively.)
To his colleagues, he's a human substitute for the Internet. "It works something like this," says news anchor Mitch Reynolds, who demonstrates on the video by opening his door and calling out, "Hey, Brad. What's [the D.A.'s] number?" Faster than you can Google it, Williams recites the listing.
There is no magic formula for achieving such a memory, although neuroscientist James McGaugh at the University of California, Irvine, is studying Williams for clues. Most of us would be happy just to keep our mental recall from slowing with age - a process that seems to start alarmingly early.
"If you're over 25, you're one of us - your memory is slipping," says neurologist Scott Small of Columbia University, who is 46.
But scientists now know that much of that deterioration represents a slowing of cognitive function rather than actual memory loss, and they're busy working on interventions. No one should expect miracles soon, if at all.
But the deeper scientists peer into the workings of memory, the better they understand what helps to stave off age-related declines - and the closer they come to devising potential drugs to help.
There are many hypotheses about why our powers of recall go awry over time, but it's clear that both committing new information to memory and retrieving it become more difficult. A new memory is fragile. "It has to set, like cement or Jell-O," says McGaugh.
A small structure in the brain called the hippocampus binds information from various parts of the brain into a coherent memory, which the prefrontal cortex later pulls up for use. But the prefrontal cortex and other brain structures tend to shrink with age, as the cells' long projections contract, taking with them some of the crucial synapses that neurons use for communication. "Paradoxically, the main result we see in brain imaging is that older people have greater brain activation, not less, probably because they're compensating," says Michael Rugg, director of the Center for the Neurobiology of Learning and Memory at UC Irvine.
For example, young people accomplish verbal memory tasks by using the language areas on the left side of the brain, while older people tend to pull in the mirror-image areas on the right side, too. This approach gets the job done, but with less efficiency and less precision.
Where there's a physiological problem, there are usually scientists trying to devise drugs, and memory is no exception. Some potential pills are now advancing to clinical trials.
One unlikely example is a class of compounds related to nicotine. Researchers have long known that it's easier to form memories when you're paying greater attention - and as smokers will attest, nicotine helps.
But nicotine from cigarettes and patches also has negative effects on the cardiovascular system, raising heart rate and blood pressure. Memory Pharmaceuticals Corp. has devised a compound that selectively tickles nicotine receptors in the brain. "You get rid of the bad effects and retain the good," says chief scientific officer David Lowe.
Last month the company announced the results of a small trial in 80 Alzheimer's patients, who performed better on tests of long-term memory, working memory and speed of cognitive processing after taking the pill once a day for eight weeks. Larger trials are still needed, meaning that it could be years before the drug comes to market, if ever.
In the meantime, other companies are exploring different ways to enhance memory formation - from increasing the intensity of brain signaling to prolonging the activity of genes that encode memories.
But poorer memory formation is only one frustration of aging brains. What about old memories you want to retrieve? Sometimes the crucial neurons that retain a memory are damaged. More often, scientists believe, memories simply become harder to access, as that annoying tip-of-the-tongue phenomenon suggests.
In a study this year in the journal Nature, neuroscientist Li-Huei Tsai at MIT provided tantalizing evidence that some "lost" memories may be recoverable, even in the presence of neuronal damage. Tsai put mice in a specially wired cage, where they received a mild shock to their feet - nothing dangerous, just unpleasant. But it made enough of an impression that the mice would tense up in fear when they were put back in the wired cage.
Memories of dangerous situations tend to be very strong, since survival hinges on recalling threats and learning to avoid them. But when Tsai triggered the degeneration of critical neurons, the mice apparently forgot their fear of the wired cage. "They no longer froze in place," she says.
The most revealing part of the experiment came in the final step, when Tsai tried two ways of boosting synaptic formation. One was placing the mice in an "enriched environment," with lots of new toys to engage their learning and attention.
The other was administering an experimental drug that promotes synapse formation. After both, the animals exhibited the fearful behavior again, without receiving any further shocks. "If they can recover these memories, that strongly indicates these memories aren't completely erased," says Tsai. "Even in severe dementia, people have brief moments of clarity."
Drugs like the one she tested in mice could conceivably enhance those periods of lucidity. But only years of testing will tell, and even then, the pills may have prohibitive side effects.
That's why many scientists are more interested in what we can accomplish naturally, without drugs. "With a reasonable amount of effort, you can improve your memory 30 to 40 percent," says Dr. Barry Gordon, founder of the memory clinic at Johns Hopkins.
In the past year, research has shed new light in particular on the benefits of both mental and physical activity. It's been known for a while that aerobic exercise increases levels of a brain chemical called BDNF, which encourages neurons to form new synapses and strengthen existing ones. "I call BDNF brain fertilizer," says Carl Cotman, director of the Institute for Brain Aging and Dementia at UC Irvine.
But in the Proceedings of the National Academy of Sciences this year, Small at Columbia showed that exercise in 11 volunteers did even more. Aerobic exercise - an hour a day, four days a week for three months - led to changes on brain scans that seemed to indicate the birth of new neurons in the hippocampus. "My lab members are dusting off their sneakers," he says.
Mental workouts, too, encourage the formation of neural connections. Last month Peter Penzes at Northwestern University published a study showing that brain activity boosts the function of a protein called kalirin-7, whose function had been unclear. Penzes demonstrated that kalirin enlarges and strengthens synapses. By contrast, blocking kalirin causes synapses to shrink. "The old saying was right - use it or lose it," he says.
But the problem with traditional memory exercises has been that practicing one type of task rarely improves performance on others. Working crossword puzzles doesn't help you remember a shopping list.
That's why a presentation last month at the Gerontological Society of America seemed so intriguing. In a study of 524 healthy adults ages 65 and over, those who worked an hour a day for eight weeks on a computer-based learning program called Brain Fitness 2.0 from Posit Science showed improvements in a variety of unrelated memory tasks. "The gains were equivalent to turning back the clock 10 years," says lead investigator Elizabeth Zelinski of the University of Southern California. By contrast, participants who were given documentaries to watch showed only marginal improvement (although improvements of any kind are better than declines).
Brain Fitness doesn't teach memory tricks, but instead asks users to discriminate between similar sounds and follow auditory commands, in a series of increasingly difficult tests. The ultimate effect is to sharpen the brain's systems of attention - although it's not clear yet how long after training the benefits will last.
But the truth is, there are limits. Even Brad Williams's memory isn't foolproof. In 1993, acting in an amateur theater production, he blanked on the name of one of the play's characters. "You'd think I'd be able to remember it," he says. "It was my own name - Williams." It's so comforting to know he's human, too.
© Newsweek, Inc.
Jogging your memory
http://bulletin.ninemsn.com.au:80/article.aspx?id=334191
Have a nice day
Erbse
Thanks for the alert on MEMY looks good for a double AT LEAST :)
Todays trading again confirms that holding down memy for a long time is not possible. Gonna break out very soon.IMO
MEMY did not trade in the last 50 minutes. somthing is coming here soon. NOT many sellers left below 60c. Ready for next move to 75c. IMO
Thanks Surf. Expecting something in Jan.Lets see.
Don't know about a 3-7 bagger, but MEMY can jump over $1 on any news and a run in Jan could take to near $2. Also, nice job on updating the MEMY iBOX.
You should be able to get 25 % to 50 % by Jan end or second week of Feb. But i expect a 3-7 bagger by April May. JMHO
bagfull - what is your time frame for a 5+ bagger?
I'm hoping for a 25% to 50% gain over the next couple of months.
I will continue to post here every few days , as I think this is a hidden gem @ this price. I see this PPS as a 5-10 bagger from this level.GL to anyone paying attention here.
Patience needed till March April time frame. Buy and forget till then.Do not put stop loss,MM's will take your stocks . JMHO
Will be a delayed run here too .IMO
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
199
|
Created
|
09/27/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |